The signalling cascade from initial stimulus to downstream effector — and where therapeutic intervention is possible at each node.
Tumour necrosis factor-alpha (TNF-α) is a pleiotropic pro-inflammatory cytokine produced predominantly by activated macrophages, T-lymphocytes, and dendritic cells. Upon release, TNF-α binds to two distinct surface receptors — TNFR1 (ubiquitously expressed) and TNFR2 (primarily on immune and endothelial cells) — triggering downstream activation of NF-κB, MAPK, and caspase-dependent apoptotic pathways. This results in amplification of the inflammatory cytokine cascade, upregulation of adhesion molecules, and ultimately tissue destruction characteristic of chronic inflammatory and autoimmune diseases.
In conditions such as rheumatoid arthritis, ankylosing spondylitis, and inflammatory bowel disease, dysregulated TNF-α signalling drives synovial pannus formation, intestinal mucosal damage, and systemic inflammation. TNF-α also plays a central role in granuloma maintenance in Crohn's disease, explaining the efficacy of TNF-α inhibition across both luminal and fistulising disease phenotypes. The cytokine's role in psoriatic skin and joint inflammation is similarly well-characterised, with elevated synovial and dermal TNF-α levels correlating with disease activity.
Therapeutic blockade of TNF-α represents one of the most clinically validated targets in modern medicine, with approved agents spanning five distinct molecular structures — chimeric monoclonals, humanised monoclonals, fully human monoclonals, fusion proteins, and PEGylated Fab fragments. This structural diversity confers differences in immunogenicity, tissue penetration, and placental transfer, with clinical implications for specific patient populations including pregnant women and those requiring dose optimisation.
Upstream blockade vs downstream blockade — understanding the distinction is critical for treatment selection and sequencing.
The downstream disease manifestations of dysregulated signalling in this pathway.
Clinically actionable insights for treatment selection and sequencing
TNF-α inhibitors require pre-treatment screening for latent tuberculosis (IGRA or Mantoux) and hepatitis B status per NICE guidance before initiation.
Certolizumab pegol is a PEGylated Fab fragment lacking an Fc region — associated with minimal placental transfer in pregnancy compared to other TNF-α inhibitors.
Immunogenicity (anti-drug antibodies) to TNF-α inhibitors can reduce trough drug levels and attenuate clinical response; therapeutic drug monitoring can guide dose optimisation.
Patients with demyelinating disease, moderate-to-severe heart failure (NYHA Class III-IV), or prior serious infection require careful risk-benefit assessment before TNF-α inhibitor initiation.
Guidelines, trials, clinical briefs, podcasts and CPD connected to this pathway.
Get Dermatology Drug Science updates, related trials and education resources in your ClinicaliQ preferences.
Complete the reflective questions and self-assessment to claim your CPD certificate for this molecular mechanism hub.
Go to CPD Centre →